Positron Emission Tomography of in-vivo Binding Characteristics of Atypical Antipsychotic Drugs Review of D2 and 5-HT2 Receptor Occupancy Studies and Clinical Response

British Journal of Psychiatry

Volumn 168, Issue MAY SUPPL. 29, 1996, Pages 40-44

  Nyberg, Svante ^a   Nakashima, Yoshifumi ^a   Nordström, Anna Lena ^a   Halldin, Christer ^a   Farde, Lars ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; RISPERIDONE; SEROTONIN RECEPTOR; CHLORPROMAZINE; DOPAMINE RECEPTOR; FLUPENTIXOL DECANOATE; HALOPERIDOL; MELPERONE; PERPHENAZINE ENANTHATE; PIMOZIDE; REMOXIPRIDE; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL;

ARTICLE; BRAIN; CLASSIFICATION; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DOSE RESPONSE; DRUG EFFECT; HUMAN; METABOLISM; PSYCHOLOGY; SCHIZOPHRENIA; SCINTISCANNING; ADULT; CLINICAL ARTICLE; DRUG BINDING; MALE; POSITRON EMISSION TOMOGRAPHY; REVIEW;

ANTIPSYCHOTIC AGENTS; BRAIN; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0029984110     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/s0007125000298309     Document Type: Article

References (43)

1. BALSARA, J. J., JADHAV, J. H. & CHANDORKAR, A. G. (1979) Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy. Psychopharmacology, 62, 67-69.
2. BARON, J. C., MARTINOT, J. L., CAMBON, H., et al (1989) Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology, 99, 463-472.
3. 2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. Clinical Neuropharmacology, 13, 500-506.
4. CARLSSON, A. & LINDQVIST, M. (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacologica et Toxicologica, 20, 140-144.
5. CEULEMANS, D. L. S., GELDERS, Y. G., HOPPENBROUWERS, M.-L. J. A., et al (1985) Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology, 85, 329-332.
6. CLAUS, A., BOLLEN, J., DE CUYPER, H., et al (1992) Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatrica Scandinavica, 85, 295-305.
7. COSTALL, B., FORTUNE, D. H., NAYLOR, R. J., et al (1975) Serotonergic involvement with neuroleptic catalepsy. Neuropharmacology, 14, 859-868.
8. CREESE, I., BURT, D. R. & SNYDER, S. H. (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science, 192, 481-483.
9. 2 dopamine receptor binding in the living human brain by PET. Science, 231, 258-261.
10. 2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology, 99, S28-S31.
11. 2-dopamine receptors studies by PET - a comparison to the equilibrium analysis. Journal of Cerebral Blood Flow Metabolism, 9, 696-708.
12. 2 dopamine receptors in neuroleptic-naïve schizophrenic patients. Archives of General Psychiatry, 47, 213-219.
13. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Archives of General Psychiatry, 49, 538-544.
14. 2 receptor blockers in the treatment of chronic schizophrenia. Clinical Neuropharmacotogy, 9 (suppl. 4), S325-S327.
15. GERLACH, J. (1991) New antipsychotics: classification, efficacy, and adverse effects. Schizophrenia Bulletin, 17, 289-309.
16. 2 binding. Nuclear Medicine Biology, 18, 871-881.
17. HICKS, P. B. (1990) The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sciences, 47, 1609-1615.
18. HYTELL, J., LARSEN, J. J., CHRISTENSEN, A. V., et al (1985) Receptor-binding profiles of neuroleptics. In Dyskinesia: Research and Treatment (eds D. E. Casey, T. N. Chase & A. V. Christensen), pp. 9-18. New York: Springer.
19. KANE, J., HONIGFELD, G., SINGER, J., et al (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789-796.
20. KORSGAARD, S., GERLACH, J. & CHRISTENSSON, E. (1985) Behavioural aspects of serotonin-dopamine interaction in the monkey. European Journal of Pharmacology, 118, 245-252.
21. KOSTOWSKI, W., GUMULKA, W. & CZLONKOWSKI, A. (1972) Reduced cataleptogenic effects of some neuroleptics in rats with lesioned midbrain raphe and treated with p-chlorophenylalinine. Brain Research, 48, 443-446.
22. LEYSEN, J. E., GOMMEREN, W., EENS, A., et al (1988) Biochemical profile of risperidone, a new antipsychotic. Journal of Pharmacology and Experimental Therapeutics, 247, 661-670.
23. LIEBERMAN, J. A. (1994) Understanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in use and development. British Journal of Psychiatry, 163 (suppl. 22), 7-18.
24. LITTON, J., BERGSTRÖM, K., ERIKSSON, L., et al(1984) Performance study of the PC-384 positron camera system for emission tomography of the brain. Computer Assisted Tomography, 8, 74-87.
25. _, HOLTE, S. & ERIKSSON, L. (1990) Evaluation of the Karolinska new positron camera system: the Scanditronix PC2048-156B. IEEE Transmission on Nuclear Science, 37, 743-748.
26. MARDER, S. R. (1992) Risperidone: clinical development: North American results. Clinical Neuropharmacology, 15 (suppl. 1, Pt A), 92A.
27. _ & MEIBACH, R. C. (1994) Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 825-835.
28. MELTZER, H. Y. (1991) The mechanism of action of novel antipsychotic drugs. Schizophrenia Bulletin, 17, 263-287.
29. _, MATSUBARA, S. & LEE, J.-C. (1989) The ratios of serotonin-2 and dopamine-2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacology Bulletin 25, 390-392.
30. MIZUKI, Y., KAJAMURA, N., IMAI, T., et al (1990) Effects of mianserin on negative symptoms in schizophrenia. International Journal of Clinical Psychopharmacology, 5, 83-95.
31. MÜLLER-SPAHN, F. (1992) Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. Clinical Neuropharmacology, 15 (suppl. 1, Pt A), 90A.
32. NORDSTRÖM, A.-L. (1993) PET Evaluation of Dopamine Hypothesis for Antipsychotic Drugs and Schizophrenia. Department of Psychiatry and Psychology, Karolinska Insitute, Stockholm, Sweden.
33. 11C]raclopride binding in healthy young adults and schizophrenic patients - reliability and age effects. Human Psychopharmacology, 7, 157-165.
34. 2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology, 110, 365-367.
35. 2 dopamine receptor occupancy in the living human brain: a PET study with risperidone. Psychopharmacology, 110, 265-272.
36. PEROUTKA, S. J. & SNYDER, S. H. (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adrenergic, and histamine receptors to clinical potency. American Journal of Psychiatry, 137, 1518-1522.
37. 2 receptor blocker. Drug Development Research, 8, 205-211.
38. SEEMAN, P., LEE, T., CHAU-WONG, M., et al (1976) Antipsychotic drug doses and neuroleptic/dopamine receptor. Nature, 261, 717-719.
39. SILVER, H, & NASSAR, A. (1992) Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biological Psychiatry, 31, 698-704.
40. _, BLACKER, M., WELLER, M. P. I., et al (1989) Treatment of chronic schizophrenia with cyproheptadine. Biological Psychiatry, 25, 502-504.
41. 18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients. Biological Psychiatry, 23, 653-663.
42. 2 receptors and antipsychotic drugs studied with PET in schizophrenia: preliminary results. (Proceedings of the AEP sixth European Congress, Barcelona, November 3-7). Anales de Psiquiatria, 8 (suppl. 1), 9.
43. VAN ROSSUM, J. M. (1966) The significance of dopamine receptor blockade for the mechanism of action of neuroleptic drugs. Archives Internationales de Pharmacodynamie et de Thérapie, 160, 492-494.